Consistently, immunohistochemical results also presented that MEF2A protein was increased in cetuximab-sensitive CRC specimens in comparison to adjacent normal tissues, while it was further upregulated in resistant CRC tissues (Fig. 1C). Here, MEF2A is linked to colorectal carcinoma.